ZymoGenetics (ZGEN) +59% premarket after Bristol-Myers (NYSE:BMY) pays $85M for its experimental...Jan. 13, 2009 9:02 AM ETZymoGenetics, Inc. (ZGEN-OLD) StockBMY, ZGEN-OLDBy: Eli Hoffmann, SA News Editor1 Comment ZymoGenetics (ZGEN) +59% premarket after Bristol-Myers (NYSE:BMY) pays $85M for its experimental hepatitis C treatment up front, and could pay as much as $1.1B based on future milestones. Recommended For YouRelated StocksSymbolLast Price% ChgZGEN-OLD--ZymoGenetics, Inc.Trending AnalysisTrending News